TABLE 1.
Vpr-IN complementation activities of IN mutant virusesa
| IN mutant | % WT activityb | Vpr-INWTc | % Vpr-INWT complementationd
|
|||
|---|---|---|---|---|---|---|
| V165A | D116A | H12N | K34A | |||
| D64N/D116N | 0.2 (0.1) | 19.3 (2.9) | 51.4 (9.9) | 0.4 (0.1) | 2.2 (1.7) | 26.5 (8.1) |
| V165A | 0.1 (0.1) | 56.1 (17.8) | 0.3 (0.1) | 3.2 (0.6) | 0.1 (0.0) | 5.0 (0.9) |
| H12N | 0.1 (0.0) | 60.8 (23.6) | 0.3 (0.1) | 0.3 (0.1) | 0.1 (0.1) | 1.2 (0.3) |
| K34A | 0.1 (0.1) | 33.3 (14.3) | 2.2 (0.5) | 1.7 (1.0) | 0.2 (0.1) | 4.3 (2.5) |
| W235E | 0.2 (0.1) | 40.6 (22.4) | 4.6 (1.5) | 8.9 (2.4) | 1.3 (0.2) | 36.8 (18.1) |
a
Average of duplicate luciferase activities following two independent infections, with standard deviation in parentheses.
b
Mutant virus activity relative to that of HIV-1NLX.Luc(R−). WT, wild type.
c
Vpr-INWT complementation activity relative to that of HIV-1NLX.Luc(R−).
d
Activity of the indicated Vpr-IN mutant protein, relative to that of Vpr-INWT.